Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088498 · ClinicalTrials.gov registry record · Phase 2
App for Reducing Cravings to Smoke
A Phase 2 study of Smoking, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 3,600
- Enrollment target
- 1
- Study location
NCT06088498: Recruiting Phase 2 study of Smoking, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06088498 is a Phase 2 study of Smoking that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3,600 participants, above the 426-participant average among 123 other Smoking trials with a reported enrollment target (745% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06088498, a Phase 2 study of Smoking, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 3,600 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.
Primary Outcome
Participants' perception of usability and learnability of the app will be measured using 10 items on a 5-point Likert scale. Scores range from 0 to 100, with higher scores indicating better usability.
Conditions Studied
Interventions
- BEHAVIORAL Updating Existing Smartphone App
- BEHAVIORAL Quitline Services
- BEHAVIORAL Quitline Services and Smartphone App
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,600 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 2 |
What NCT06088498 shows while recruiting
NCT06088498 is an interventional study that assigns participants to a tested intervention. Its 3,600 participants enrollment target places it among the larger protocols in the corpus, above the 426-participant average among 123 other Smoking trials with a reported enrollment target (745% higher).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 3 interventions - of which Updating Existing Smartphone App is the first listed.
NCT06088498 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06088498 about?
NCT06088498 is a clinical study titled "App for Reducing Cravings to Smoke". The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.
What is the current status of trial NCT06088498?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 3,600 participants. The study started on 2024-06-11. Estimated completion is 2027-05-01.
What conditions does trial NCT06088498 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT06088498?
The interventions under investigation include: Updating Existing Smartphone App (BEHAVIORAL), Quitline Services (BEHAVIORAL), Quitline Services and Smartphone App (BEHAVIORAL).
Who is sponsoring clinical trial NCT06088498?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088498 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06088498's enrollment target sits among peer trials
3,600 2nd of 123 the highest of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
-
Oxidative Stress and Vitamin E Requirements
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
- NCT07091032 · 3,600 participants · NA
Building Connections
- NCT03199651 · 3,584 participants · NA
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI